# Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

> **NCT00308685** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 95 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Albuterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00308685
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-10
- **Primary completion:** 2006-12-04
- **Final completion:** 2006-12-04
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308685, "Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00308685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*